Mocroft A, Katlama C, Johnson A M, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips A N, Kirk O, Lundgren J D
Royal Free Centre for HIV Medicine, Royal Free and University College London Medical School, UK.
Lancet. 2000 Jul 22;356(9226):291-6. doi: 10.1016/s0140-6736(00)02504-6.
The clinical presentation of HIV-1 related diseases could have changed after the introduction of highly active antiretroviral treatment (HAART). We aimed to assess changes over time in the incidence of ADIs overall and within CD4 lymphocyte count strata, the relationship with treatment and degree of immunodeficiency at diagnosis of ADIs.
We did a prospective observational multicentre study of over 7300 patients in 52 European HIV-1 outpatient clinics. Incidence rates per 100 patient-years of observation were calculated.
In total, we recorded 1667 new ADIs; the incidence of ADIs declined from 30.7 per 100 patient-years of observation during 1994 (95% CI 28.0-33.4) to 2.5 per 100 patient-years of observation during 1998 (95% CI 2.0-3.0, p<0.0001, test for trend). Median CD4 lymphocyte count at diagnosis of a new ADI increased from 28 cells/microL to 125 cells/microL between 1994 and 1998 (p<0.0001), yet a steep decline in the rate of ADIs was seen after stratification by latest CD4 lymphocyte count within each year (< or = 50, 51-200, and > 200 cells/microL). Patients on HAART had a lower rate of ADIs than patients not on this treatment within each CD4 lymphocyte count strata. The proportion of ADIs attributable to cytomegalovirus retinitis and Mycobacterium avium complex declined over time (p=0.0058 and 0.0022, respectively), whereas the proportion of diagnoses attributable to non-Hodgkin lymphoma has increased (p<0.0001). In 1994, less than 4% of ADIs were non-Hodgkin lymphoma, in 1998 the proportion was almost 16%. This condition has become one of the most common ADIs in patients on HAART.
Our findings lend support to the idea that treatment regimens can lower the incidence of ADIs. The immediate risk of an ADI for a given CD4 lymphocyte count has declined over time and is lower among patients on HAART. Long-term follow-up of patients on combination treatment is essential to monitor the incidence of new and emerging diagnoses.
高效抗逆转录病毒治疗(HAART)引入后,HIV-1相关疾病的临床表现可能已发生变化。我们旨在评估艾滋病相关疾病(ADIs)总体发病率以及在CD4淋巴细胞计数分层内随时间的变化,ADIs诊断时与治疗及免疫缺陷程度的关系。
我们在欧洲52家HIV-1门诊对7300多名患者进行了一项前瞻性观察性多中心研究。计算每100患者年观察期的发病率。
我们共记录了1667例新发ADIs;ADIs的发病率从1994年每100患者年观察期的30.7例(95%可信区间28.0 - 33.4)降至1998年每100患者年观察期的2.5例(95%可信区间2.0 - 3.0,p<0.0001,趋势检验)。1994年至1998年期间,新诊断ADIs时的CD4淋巴细胞计数中位数从28个/微升增至125个/微升(p<0.0001),然而按每年最新CD4淋巴细胞计数分层(≤50、51 - 200以及>200个/微升)后,ADIs发病率仍急剧下降。在每个CD4淋巴细胞计数分层内,接受HAART治疗的患者ADIs发病率低于未接受该治疗的患者。归因于巨细胞病毒性视网膜炎和鸟分枝杆菌复合体的ADIs比例随时间下降(分别为p = 0.0058和0.0022),而归因于非霍奇金淋巴瘤的诊断比例有所增加(p<0.0001)。1994年,不到4%的ADIs为非霍奇金淋巴瘤,1998年这一比例近16%。这种疾病已成为接受HAART治疗患者中最常见的ADIs之一。
我们的研究结果支持治疗方案可降低ADIs发病率这一观点。给定CD4淋巴细胞计数时发生ADIs的直接风险随时间下降,且在接受HAART治疗的患者中更低。对联合治疗患者进行长期随访对于监测新出现诊断的发病率至关重要。